Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22071596,half-life,Peak plasma concentrations of afatinib were reached 3-4 h after administration and declined with a half-life of 30-40 h.,Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22071596/),h,30-40,22,DB00530,Erlotinib
,26420235,disease control rate,"No objective responses were observed; the disease control rate was 27 % (95 % CI, 6-61 %).","Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26420235/),%,27,223,DB00530,Erlotinib
,32654250,time to progression,The median time to progression was 2.2 months.,Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654250/),month,2.2,564,DB00530,Erlotinib
,32654250,clearance rate,"The clearance rate was 30.0% (95% confidence interval [CI]: 11.9%-54.3%), the median TTP was 2.2 months, and the median OS was 3.4 months.",Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654250/),%,30.0,565,DB00530,Erlotinib
,32654250,cerebrospinal fluid penetration rate,The mean cerebrospinal fluid penetration rate was 3.31% ± 0.77%.,Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654250/),%,3.31,566,DB00530,Erlotinib
,27422720,disease control rate,A best response of stable disease was achieved by 2/11 patients in Part A and 4/6 patients in Part B (disease control rate: 35 %).,"A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27422720/),%,35,8740,DB00530,Erlotinib
,24901237,clearance,"Pharmacokinetics of ficlatuzumab showed low clearance (0.17-0.26 ml h(-1) kg(-1)), a half-life of 6.8-9.4 days and dose-proportional exposure.",Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24901237/),[ml] / [h·kg],0.17-0.26,14215,DB00530,Erlotinib
,24901237,half-life,"Pharmacokinetics of ficlatuzumab showed low clearance (0.17-0.26 ml h(-1) kg(-1)), a half-life of 6.8-9.4 days and dose-proportional exposure.",Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24901237/),d,6.8-9.4,14216,DB00530,Erlotinib
,30945322,ratio,The quinine/3-OH-quinine ratio decreased from 20.2 (± 13.4) at baseline to 11.0 (± 4.34).,Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945322/),,20.2,18416,DB00530,Erlotinib
,30945322,ratio,The quinine/3-OH-quinine ratio decreased from 20.2 (± 13.4) at baseline to 11.0 (± 4.34).,Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945322/),,11.0,18417,DB00530,Erlotinib
,25678398,apparent pH*,"Separation was achieved on a reversed phase C18 column (50×2mm, 5μm) at ambient temperature using isocratic elution with acetonitrile-water (45:55, v/v) containing 5mM ammonium formate buffer (finally adjusted to apparent pH*=5.0 with formic acid) at a flow rate of 0.4mL/min.",An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678398/),,5.0,18810,DB00530,Erlotinib
,25678398,flow rate,"Separation was achieved on a reversed phase C18 column (50×2mm, 5μm) at ambient temperature using isocratic elution with acetonitrile-water (45:55, v/v) containing 5mM ammonium formate buffer (finally adjusted to apparent pH*=5.0 with formic acid) at a flow rate of 0.4mL/min.",An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25678398/),[ml] / [min],0.4,18811,DB00530,Erlotinib
,24408299,total LC analysis time per injection,The total LC analysis time per injection was 4 min with a flow rate of 0.2 mL/min.,Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24408299/),min,4,19914,DB00530,Erlotinib
,24408299,flow rate,The total LC analysis time per injection was 4 min with a flow rate of 0.2 mL/min.,Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24408299/),[ml] / [min],0.2,19915,DB00530,Erlotinib
greater,24408299,recovery,The recovery was greater than 90% and no significant matrix effect was observed.,Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24408299/),%,90,19916,DB00530,Erlotinib
,27796680,Ce,"Over 75 years old, the mean Ce was 1.5 fold higher: 2091 ng/mL (95 % CI [1476; 2706]) vs 1359 (95 % CI [1029; 1689]; p = 0.024).",Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27796680/),[ng] / [ml],2091,22914,DB00530,Erlotinib
,27796680,Ce,"Over 75 years old, the mean Ce was 1.5 fold higher: 2091 ng/mL (95 % CI [1476; 2706]) vs 1359 (95 % CI [1029; 1689]; p = 0.024).",Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27796680/),,1359,22915,DB00530,Erlotinib
,27796680,Ce,"In pts. over 80 years old, the mean Ce was doubled: 2729 (95 % CI [1961; 3497]) vs 1358 ng/mL (95 % CI [1070; 1646]; p = 0.0019).",Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27796680/),[ng] / [ml],2729,22916,DB00530,Erlotinib
,27796680,Ce,"In pts. over 80 years old, the mean Ce was doubled: 2729 (95 % CI [1961; 3497]) vs 1358 ng/mL (95 % CI [1070; 1646]; p = 0.0019).",Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27796680/),[ng] / [ml],1358,22917,DB00530,Erlotinib
,19956953,plasma concentration cap,The MTD for IV erlotinib was not reached as a predetermined erlotinib plasma concentration cap of 4 microg/mL was exceeded in 3/6 patients.,"A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19956953/),,4,24876,DB00530,Erlotinib
,19956953,bioavailability,Median bioavailability of erlotinib tablets was 76%.,"A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19956953/),%,76,24877,DB00530,Erlotinib
,17332296,AUC(0-24),"Whereas erlotinib and OSI-420 AUC(0-24) in plasma on day 34 were 30,365 and 2,527 ng h/mL, respectively, the correspondent AUC(0-24) in the CSF were 2,129 and 240 ng h/mL, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),[h·ng] / [ml],"30,365",25743,DB00530,Erlotinib
,17332296,AUC(0-24),"Whereas erlotinib and OSI-420 AUC(0-24) in plasma on day 34 were 30,365 and 2,527 ng h/mL, respectively, the correspondent AUC(0-24) in the CSF were 2,129 and 240 ng h/mL, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),[h·ng] / [ml],"2,527",25744,DB00530,Erlotinib
,17332296,AUC(0-24),"Whereas erlotinib and OSI-420 AUC(0-24) in plasma on day 34 were 30,365 and 2,527 ng h/mL, respectively, the correspondent AUC(0-24) in the CSF were 2,129 and 240 ng h/mL, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),[h·ng] / [ml],"2,129",25745,DB00530,Erlotinib
,17332296,AUC(0-24),"Whereas erlotinib and OSI-420 AUC(0-24) in plasma on day 34 were 30,365 and 2,527 ng h/mL, respectively, the correspondent AUC(0-24) in the CSF were 2,129 and 240 ng h/mL, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),[h·ng] / [ml],240,25746,DB00530,Erlotinib
,17332296,penetration,"Erlotinib and OSI-420 CSF penetration were 7% and approximately 9%, respectively, using both estimate methods.",Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),%,7,25747,DB00530,Erlotinib
,17332296,penetration,"Erlotinib and OSI-420 CSF penetration were 7% and approximately 9%, respectively, using both estimate methods.",Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),%,9,25748,DB00530,Erlotinib
,17332296,maximum steady-state CSF concentration,The maximum steady-state CSF concentration of erlotinib was approximately 130 ng/mL (325 nmol/L).,Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332296/),[ng] / [ml],130,25749,DB00530,Erlotinib
,33196042,mPFS,"The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2) for arm B, and 14.5 ± 7.8 (6.7-22.3) for arm C.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),month,11.4,26195,DB00530,Erlotinib
,33196042,mPFS,"The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2) for arm B, and 14.5 ± 7.8 (6.7-22.3) for arm C.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,8.7,26196,DB00530,Erlotinib
,33196042,mPFS,"The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2) for arm B, and 14.5 ± 7.8 (6.7-22.3) for arm C.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,14.5,26197,DB00530,Erlotinib
,33196042,Intracranial response rate,Intracranial response rate to dose escalation was 54% (6 of 11) with 2 of 11 having intracranial stability.,Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),%,54,26198,DB00530,Erlotinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),month,4.3,26199,DB00530,Erlotinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,3.8,26200,DB00530,Erlotinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,5.6,26201,DB00530,Erlotinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,7.0,26202,DB00530,Erlotinib
,20150372,tissue-to-plasma ratio,"The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients.",A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150372/),%,25,32168,DB00530,Erlotinib
,20150372,tissue-to-plasma ratio,"The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients.",A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150372/),%,44,32169,DB00530,Erlotinib
,20150372,tissue-to-plasma ratio,"The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients.",A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150372/),%,30,32170,DB00530,Erlotinib
,20150372,tissue-to-plasma ratio,"The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients.",A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150372/),%,59,32171,DB00530,Erlotinib
,24121455,progression-free survival (PFS),"The median progression-free survival (PFS) and overall survival (OS) were 6.3 months and 16.9 months, respectively.",Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24121455/),month,6.3,32699,DB00530,Erlotinib
,24121455,overall survival (OS),"The median progression-free survival (PFS) and overall survival (OS) were 6.3 months and 16.9 months, respectively.",Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24121455/),month,16.9,32700,DB00530,Erlotinib
,24121455,PFS,"The median PFS of the high and low D8/D2 ratio group was 11.2 months and 5.7 months, respectively (p = 0.044, hazard ratio = 0.301, 95 % CI 0.094–0.968).",Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24121455/),month,11.2,32701,DB00530,Erlotinib
,24121455,PFS,"The median PFS of the high and low D8/D2 ratio group was 11.2 months and 5.7 months, respectively (p = 0.044, hazard ratio = 0.301, 95 % CI 0.094–0.968).",Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24121455/),month,5.7,32702,DB00530,Erlotinib
,17538162,response,"The intention-to-treat response rate was 21%, with one complete and eight partial responses (95% CI, 10% to 36%), and disease stabilization was achieved in 21 patients (49%; 95% CI, 33% to 65%).",Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538162/),,21,34262,DB00530,Erlotinib
,17538162,progression-free survival,"Median progression-free survival was 3.3 months (95% CI, 2.7 to 4.8 months) and median overall survival was 7.9 (95% CI, 5.6 to 9.5) months.",Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538162/),month,3.3,34263,DB00530,Erlotinib
,17538162,overall survival,"Median progression-free survival was 3.3 months (95% CI, 2.7 to 4.8 months) and median overall survival was 7.9 (95% CI, 5.6 to 9.5) months.",Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538162/),month,7.9,34264,DB00530,Erlotinib
,31392390,CL/F,"Erlotinib and OSI-420 apparent clearances (CL/F and CLm/Fm) were higher in patients < 5 years compared to older patients (mean CL/F: 6.8 vs 3.6 L/h/m2, and mean CLm/Fm: 79 vs 38 L/h/m2, p < 0.001), and were 1.62-fold and 1.73-fold higher in males compared to females (p < 0.01).",Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31392390/),[l] / [h·m2],6.8,37735,DB00530,Erlotinib
,31392390,CL/F,"Erlotinib and OSI-420 apparent clearances (CL/F and CLm/Fm) were higher in patients < 5 years compared to older patients (mean CL/F: 6.8 vs 3.6 L/h/m2, and mean CLm/Fm: 79 vs 38 L/h/m2, p < 0.001), and were 1.62-fold and 1.73-fold higher in males compared to females (p < 0.01).",Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31392390/),[l] / [h·m2],3.6,37736,DB00530,Erlotinib
,31392390,CLm/Fm,"Erlotinib and OSI-420 apparent clearances (CL/F and CLm/Fm) were higher in patients < 5 years compared to older patients (mean CL/F: 6.8 vs 3.6 L/h/m2, and mean CLm/Fm: 79 vs 38 L/h/m2, p < 0.001), and were 1.62-fold and 1.73-fold higher in males compared to females (p < 0.01).",Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31392390/),[l] / [h·m2],79,37737,DB00530,Erlotinib
,31392390,CLm/Fm,"Erlotinib and OSI-420 apparent clearances (CL/F and CLm/Fm) were higher in patients < 5 years compared to older patients (mean CL/F: 6.8 vs 3.6 L/h/m2, and mean CLm/Fm: 79 vs 38 L/h/m2, p < 0.001), and were 1.62-fold and 1.73-fold higher in males compared to females (p < 0.01).",Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31392390/),[l] / [h·m2],38,37738,DB00530,Erlotinib
,21553932,Absolute bioavailability,Absolute bioavailability of gefitinib and erlotinib is about 60%.,Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553932/),%,60,50892,DB00530,Erlotinib
,30562699,IC50,"Among them, 12h, 12l and 12m showed IC50 values: 3.82, 5.33 and 4.21 μM, respectively, on A549 cell with respect to the positive control, Erlotinib (IC50 value: 10.26 μM).","Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562699/),μM,3.82,52763,DB00530,Erlotinib
,30562699,IC50,"Among them, 12h, 12l and 12m showed IC50 values: 3.82, 5.33 and 4.21 μM, respectively, on A549 cell with respect to the positive control, Erlotinib (IC50 value: 10.26 μM).","Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562699/),μM,5.33,52764,DB00530,Erlotinib
,30562699,IC50,"Among them, 12h, 12l and 12m showed IC50 values: 3.82, 5.33 and 4.21 μM, respectively, on A549 cell with respect to the positive control, Erlotinib (IC50 value: 10.26 μM).","Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562699/),μM,4.21,52765,DB00530,Erlotinib
,30562699,IC50,"Among them, 12h, 12l and 12m showed IC50 values: 3.82, 5.33 and 4.21 μM, respectively, on A549 cell with respect to the positive control, Erlotinib (IC50 value: 10.26 μM).","Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562699/),μM,10.26,52766,DB00530,Erlotinib
,21878940,progression-free survival,"Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months, respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P=0.051).",Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878940/),month,2.3,55711,DB00530,Erlotinib
,21878940,PFS,"Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months, respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P=0.051).",Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878940/),month,3.5,55712,DB00530,Erlotinib
,21878940,PFS,"Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months, respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P=0.051).",Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878940/),month,1.9,55713,DB00530,Erlotinib
,17312388,"C(ss,min)/C(1,min)","Gefitinib accumulation during 28 days of treatment (C(ss,min)/C(1,min)) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004).",Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312388/),,5.07,56187,DB00530,Erlotinib
,17312388,"C(ss,min)/C(1,min)","Gefitinib accumulation during 28 days of treatment (C(ss,min)/C(1,min)) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004).",Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312388/),,3.60,56188,DB00530,Erlotinib
,24643910,MM constant (Km),"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,10.14,58786,DB00530,Erlotinib
,24643910,MM constant (Km),"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,2.72,58787,DB00530,Erlotinib
,24643910,Vmax,"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],6.95,58788,DB00530,Erlotinib
,24643910,Vmax,"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],75.95,58789,DB00530,Erlotinib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,12.18,58790,DB00530,Erlotinib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,7.84,58791,DB00530,Erlotinib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,4.37,58792,DB00530,Erlotinib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],15.34,58793,DB00530,Erlotinib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],6.75,58794,DB00530,Erlotinib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],194.64,58795,DB00530,Erlotinib
,32028611,pKa,"ABN401 was found to be a weak basic compound, with pKa and log P values of 7.49 and 2.46, respectively.",New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32028611/),,7.49,58938,DB00530,Erlotinib
,32028611,log P,"ABN401 was found to be a weak basic compound, with pKa and log P values of 7.49 and 2.46, respectively.",New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32028611/),,2.46,58939,DB00530,Erlotinib
,32028611,bioavailability,"The bioavailability is approximately 30% in dogs and it is highly efficient in the PDX model, achieving around 90% tumor growth inhibition in combination with erlotinib.",New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32028611/),%,30,58940,DB00530,Erlotinib
,10525095,ED(50),"CP-358,774 is an effective, orally active inhibitor of EGFr-specific tyrosine phosphorylation (ED(50) = 10 mg/kg, single dose).","Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10525095/),[mg] / [kg],10,60706,DB00530,Erlotinib
,10525095,ED(50),Substantial growth inhibition of human tumor xenografts was achieved with p.o. doses of the compound (ED(50) = 10 mg/kg q.d. for 20 days).,"Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10525095/),mg,10,60707,DB00530,Erlotinib
,21079958,progression-free survival (PFS),Median progression-free survival (PFS) for the doublet therapy was 6.0 months (0.5 to 32+ months) and 5.5 months (0.8 to 27+ months) for the triplet therapy.,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),month,6.0,63224,DB00530,Erlotinib
,21079958,progression-free survival (PFS),Median progression-free survival (PFS) for the doublet therapy was 6.0 months (0.5 to 32+ months) and 5.5 months (0.8 to 27+ months) for the triplet therapy.,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),month,5.5,63225,DB00530,Erlotinib
,21079958,Systemic exposure,Systemic exposure of everolimus was significantly higher in combination with erlotinib (476 ± 161 ng h/mL) compared to when given alone (393 ± 156 ng h/mL; P = 0.020).,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),[h·ng] / [ml],476,63226,DB00530,Erlotinib
,21079958,Systemic exposure,Systemic exposure of everolimus was significantly higher in combination with erlotinib (476 ± 161 ng h/mL) compared to when given alone (393 ± 156 ng h/mL; P = 0.020).,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),[h·ng] / [ml],393,63227,DB00530,Erlotinib
,25682545,half maximal inhibitory concentration (IC50),"Mean erlotinib tissue concentrations extrapolated to a time point directly after intake of erlotinib were approximated at > 200 ng/g tissue, which is greater than the reported half maximal inhibitory concentration (IC50) of wild type epidermal growth factor receptor (EGFR) (183 ng/mL).",Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25682545/),[ng] / [ml],183,70017,DB00530,Erlotinib
,25170013,MTD,MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),mg,150,73536,DB00530,Erlotinib
,25170013,MTD,MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),mg,70,73537,DB00530,Erlotinib
,25170013,overall disease control rate,The 35 NSCLC patients treated in phase II had an overall disease control rate of 59% at 6 weeks.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),%,59,73538,DB00530,Erlotinib
,25170013,PFS,Median PFS was 3.3 months.,A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170013/),month,3.3,73539,DB00530,Erlotinib
,28144730,area under the curve (AUC),"The mean area under the curve (AUC) value was 2640 μg/day/mL; the Cmax value was 434 μg/mL, respectively.","Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144730/),[μg] / [d·ml],2640,77549,DB00530,Erlotinib
,28144730,Cmax,"The mean area under the curve (AUC) value was 2640 μg/day/mL; the Cmax value was 434 μg/mL, respectively.","Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144730/),[μg] / [ml],434,77550,DB00530,Erlotinib
,28144730,progression-free survival,The median progression-free survival (95% confidence interval) was 220.0 (100.0-363.0) days.,"Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144730/),d,220.0,77551,DB00530,Erlotinib
,26525154,flow rate,The three drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2 mL/min for 5 min.,"Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525154/),[ml] / [min],0.2,78501,DB00530,Erlotinib
,32315488,progression-free survival (mPFS),Median progression-free survival (mPFS) was 9.3 months.,Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),month,9.3,84902,DB00530,Erlotinib
≥,32315488,trough concentration ( C min ss ),"In receiver operating characteristic (ROC) analysis of mPFS, the trough concentration ( C min ss ) was ≥ 0.30 μg/mL.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [ml],0.30,84903,DB00530,Erlotinib
≥,32315488,C min ss,"In ROC analysis of mPFS and TOX20 in the PopPK100 study, C min ss was ≥ 0.17 and < 0.32 μg/mL, respectively.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [ml],0.17,84904,DB00530,Erlotinib
<,32315488,C min ss,"In ROC analysis of mPFS and TOX20 in the PopPK100 study, C min ss was ≥ 0.17 and < 0.32 μg/mL, respectively.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [ml],0.32,84905,DB00530,Erlotinib
≥,32315488,C min ss,"In ROC analysis of mPFS and TOX20 in the PopPK100 study, C min ss was ≥ 0.15 and < 0.31 μg/mL, AUC was ≥ 14.4 and < 14.5 μg/mL•hour, and the dosage was ≥ 58.4 and < 58.8 mg/day, respectively.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [ml],0.15,84906,DB00530,Erlotinib
<,32315488,C min ss,"In ROC analysis of mPFS and TOX20 in the PopPK100 study, C min ss was ≥ 0.15 and < 0.31 μg/mL, AUC was ≥ 14.4 and < 14.5 μg/mL•hour, and the dosage was ≥ 58.4 and < 58.8 mg/day, respectively.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [ml],0.31,84907,DB00530,Erlotinib
≥,32315488,AUC,"In ROC analysis of mPFS and TOX20 in the PopPK100 study, C min ss was ≥ 0.15 and < 0.31 μg/mL, AUC was ≥ 14.4 and < 14.5 μg/mL•hour, and the dosage was ≥ 58.4 and < 58.8 mg/day, respectively.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [h·ml],14.4,84908,DB00530,Erlotinib
<,32315488,AUC,"In ROC analysis of mPFS and TOX20 in the PopPK100 study, C min ss was ≥ 0.15 and < 0.31 μg/mL, AUC was ≥ 14.4 and < 14.5 μg/mL•hour, and the dosage was ≥ 58.4 and < 58.8 mg/day, respectively.",Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32315488/),[μg] / [h·ml],14.5,84909,DB00530,Erlotinib
,18249110,Overall response rate,"Overall response rate was 67%, comprising two complete and 12 partial responders in 21 assessable patients.",Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18249110/),%,67,95867,DB00530,Erlotinib
,30830506,relative bioavailability,In vivo pharmacokinetic studies of EVLF in rats demonstrated a 199% relative bioavailability compared to ERL suspension.,Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30830506/),%,199,96575,DB00530,Erlotinib
>,25582505,extraction efficiency,"The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%.","Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582505/),%,90.5,101195,DB00530,Erlotinib
,18281547,clearance,"The clearance of docetaxel and erlotinib of 61.7 and 8.16 L/h, respectively, did not seem to differ from historical controls.",A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281547/),[l] / [h],61.7,101299,DB00530,Erlotinib
,18281547,clearance,"The clearance of docetaxel and erlotinib of 61.7 and 8.16 L/h, respectively, did not seem to differ from historical controls.",A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18281547/),[l] / [h],8.16,101300,DB00530,Erlotinib
,22407177,MTD,"The dasatinib MTD was 180 mg when combined with either 150 mg of erlotinib for patients not on EIAEDs, or 450 mg of erlotinib for patients on EIAEDs.",Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407177/),mg,180,105258,DB00530,Erlotinib
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,39,107053,DB00530,Erlotinib
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,278.04,107054,DB00530,Erlotinib
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,372.25,107055,DB00530,Erlotinib
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,72.01,107056,DB00530,Erlotinib
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,294.18,107057,DB00530,Erlotinib
>,27336702,m/z,"Quantitation was carried out using the positive ionization mode with multiple reaction monitoring (MRM) at m/z 394.20>278.04 (ERL), m/z 372.25>72.01 (TAM), and m/z 294.18>170.16 (OND).",Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27336702/),,170.16,107058,DB00530,Erlotinib
,26428157,Cmax,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [ml],134.29,109323,DB00530,Erlotinib
,26428157,Cmax,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [ml],42.36,109324,DB00530,Erlotinib
,26428157,AUC0-∞,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [h·ml],2103.47,109325,DB00530,Erlotinib
,26428157,AUC0-∞,In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),[μg] / [h·ml],580.43,109326,DB00530,Erlotinib
,26428157,Tmax,The complex exhibited 3.2-fold increase in Cmax with 5.4-fold decrease in Tmax (0.5 ± 0.2 vs. 2.7 ± 0.8h) in comparison to pure ERL.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),h,0.5,109327,DB00530,Erlotinib
,26428157,Tmax,The complex exhibited 3.2-fold increase in Cmax with 5.4-fold decrease in Tmax (0.5 ± 0.2 vs. 2.7 ± 0.8h) in comparison to pure ERL.,"Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428157/),h,2.7,109328,DB00530,Erlotinib
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,50,109626,DB00530,Erlotinib
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,75,109627,DB00530,Erlotinib
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,100,109628,DB00530,Erlotinib
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,125,109629,DB00530,Erlotinib
,24637575,Ki,"Results showed a time-dependent inhibition of MDZ metabolism by erlotinib, with a Ki of 7.5 µmol/l and an inactivation rate constant of 0.009/min.","Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24637575/),[μM] / [l],7.5,111778,DB00530,Erlotinib
,24637575,inactivation rate constant,"Results showed a time-dependent inhibition of MDZ metabolism by erlotinib, with a Ki of 7.5 µmol/l and an inactivation rate constant of 0.009/min.","Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24637575/),1/[min],0.009,111779,DB00530,Erlotinib
,27686971,progression-free survival,"The median progression-free survival for the linsitinib versus the placebo group was 8.4 months versus 12.4 months (hazard ratio, 1.37; P = .29).",Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),month,8.4,112609,DB00530,Erlotinib
,27686971,progression-free survival,"The median progression-free survival for the linsitinib versus the placebo group was 8.4 months versus 12.4 months (hazard ratio, 1.37; P = .29).",Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),month,12.4,112610,DB00530,Erlotinib
,27686971,Overall response rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,47.7,112611,DB00530,Erlotinib
,27686971,Overall response rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,75.0,112612,DB00530,Erlotinib
,27686971,disease control rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,77.3,112613,DB00530,Erlotinib
,27686971,disease control rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,95.5,112614,DB00530,Erlotinib
,23008811,flow rate,"The analytes were separated on a reverse-phase C(18) column (50mm×4.6mm i.d., 3μ) using methanol: 2 mM ammonium acetate buffer, and pH 4.0 as the mobile phase at a flow rate 0.8 mL/min.","Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23008811/),[ml] / [min],0.8,114474,DB00530,Erlotinib
greater,12906916,overall extraction efficiency,"The overall extraction efficiency was greater than 88% for OSI-774 and 62% for OSI-420, with values for within-day and between-day precision and accuracy of <15%.",Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906916/),%,88,117030,DB00530,Erlotinib
,12906916,overall extraction efficiency,"The overall extraction efficiency was greater than 88% for OSI-774 and 62% for OSI-420, with values for within-day and between-day precision and accuracy of <15%.",Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906916/),%,62,117031,DB00530,Erlotinib
,25402940,CL/F,"The estimated population pharmacokinetics parameters were as follows: 4·71 L/h for CL/F, 163 L for apparent volume of distribution (Vc /F) and 1·97 h(-1) for absorption rate constant (Ka ).",Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402940/),[l] / [h],4·71,118474,DB00530,Erlotinib
,25402940,apparent volume of distribution (Vc /F),"The estimated population pharmacokinetics parameters were as follows: 4·71 L/h for CL/F, 163 L for apparent volume of distribution (Vc /F) and 1·97 h(-1) for absorption rate constant (Ka ).",Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402940/),l,163,118475,DB00530,Erlotinib
,25402940,absorption rate constant (Ka ),"The estimated population pharmacokinetics parameters were as follows: 4·71 L/h for CL/F, 163 L for apparent volume of distribution (Vc /F) and 1·97 h(-1) for absorption rate constant (Ka ).",Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402940/),1/[h],1·97,118476,DB00530,Erlotinib
,16890575,oral clearance,"On the basis of the final model developed from patients treated with erlotinib as a single agent, the oral clearance was 3.95 L/h, the oral volume of distribution was 233 L, and the absorption rate was 0.95 h(-1).",Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890575/),[l] / [h],3.95,120197,DB00530,Erlotinib
,16890575,oral volume of distribution,"On the basis of the final model developed from patients treated with erlotinib as a single agent, the oral clearance was 3.95 L/h, the oral volume of distribution was 233 L, and the absorption rate was 0.95 h(-1).",Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890575/),l,233,120198,DB00530,Erlotinib
,16890575,absorption rate,"On the basis of the final model developed from patients treated with erlotinib as a single agent, the oral clearance was 3.95 L/h, the oral volume of distribution was 233 L, and the absorption rate was 0.95 h(-1).",Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890575/),1/[h],0.95,120199,DB00530,Erlotinib
,16890575,half-life,The median erlotinib half-life based on this patient population was 36.2 hours.,Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890575/),h,36.2,120200,DB00530,Erlotinib
,20716591,PFS-6,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),%,28,123842,DB00530,Erlotinib
,20716591,PFS-6,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),weeks,42,123843,DB00530,Erlotinib
,20716591,PFS-6,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),%,44,123844,DB00530,Erlotinib
,20716591,PFS-6,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),weeks,71,123845,DB00530,Erlotinib
,20716591,OS,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),weeks,42,123846,DB00530,Erlotinib
,20716591,OS,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),%,44,123847,DB00530,Erlotinib
,20716591,OS,"PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively.",Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20716591/),weeks,71,123848,DB00530,Erlotinib
,24096601,IC50,The time course of pEGFR degradation was reasonably fit by the indirect response model with a calculated IC50 value of 1.80 μg/mL.,Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096601/),[μg] / [ml],1.80,124439,DB00530,Erlotinib
,24096601,Kbio,"The relationship between pEGFR levels and tumor volume was characterized by the integrated model with a Kbio value of 0.507 cm(3)/week, which described the impact of pEGFR degradation on tumor growth.",Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096601/),[cm(3] / [week],0.507,124440,DB00530,Erlotinib
,28073786,progression-free survival,Median progression-free survival was 9.9 months (95% CI 5.8-15.4 months).,Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28073786/),month,9.9,128145,DB00530,Erlotinib
,22875639,detection limit,The relation between the fluorescence intensity and concentration was found to be linear (r(2) 0.9998) over the range 125 to 1000 ng/mL with the detection limit of 15 ng/mL.,Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875639/),[ng] / [ml],15,131834,DB00530,Erlotinib
,22875639,absolute recoveries,"The mean absolute recoveries of ETB were 85.59 % (±0.57), 86.91 % (±1.77) and 89.31 % (±3.01) at spiked plasma ETB concentration of 5000, 3750 and 2500 ng/mL, respectively.",Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875639/),%,85.59,131835,DB00530,Erlotinib
,22875639,absolute recoveries,"The mean absolute recoveries of ETB were 85.59 % (±0.57), 86.91 % (±1.77) and 89.31 % (±3.01) at spiked plasma ETB concentration of 5000, 3750 and 2500 ng/mL, respectively.",Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875639/),%,86.91,131836,DB00530,Erlotinib
,22875639,absolute recoveries,"The mean absolute recoveries of ETB were 85.59 % (±0.57), 86.91 % (±1.77) and 89.31 % (±3.01) at spiked plasma ETB concentration of 5000, 3750 and 2500 ng/mL, respectively.",Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875639/),%,89.31,131837,DB00530,Erlotinib
,22271880,overall response rate,"On completion of concurrent chemoradiotherapy, overall response rate derived from tumor measurements based on imaging studies was 83% for all dose levels combined.",A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271880/),%,83,133409,DB00530,Erlotinib
,18506181,MTD,The MTD of erlotinib in this regimen was determined to be 75 mg day(-1) (cohort 2b; the erlotinib dose was escalated to 100 mg day(-1) in 11 out of 19 patients from cycle 2 onwards).,"A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18506181/),[mg] / [day],75,141625,DB00530,Erlotinib
,26149476,Cmax,"Erlotinib exposure (average Cmax 2308±698 ng/ml and AUC 0-24 41,030±15,577 ng×h/ml) approximated previous reports in the six patients with pharmacokinetic analysis.",Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149476/),[ng] / [ml],2308,141644,DB00530,Erlotinib
,26149476,AUC 0-24,"Erlotinib exposure (average Cmax 2308±698 ng/ml and AUC 0-24 41,030±15,577 ng×h/ml) approximated previous reports in the six patients with pharmacokinetic analysis.",Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149476/),[h·ng] / [ml],"41,030",141645,DB00530,Erlotinib
,20094773,AUC,"1,079 previously untreated patients with advanced NSCLC were enrolled and randomized in a phase III trial (TRIBUTE) to receive either erlotinib or placebo in combination with paclitaxel 200 mg/m2 IV over 3 h and carboplatin at a calculated dose to achieve an AUC 6 mg∙min/mL.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[mg∙min] / [ml],6,144659,DB00530,Erlotinib
,20094773,AUC(0-τ),"Mean AUC(0-τ) for erlotinib and the OSI-420 metabolite were 29,997 ng∙h/mL and 3,020 ng∙h/mL, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"29,997",144660,DB00530,Erlotinib
,20094773,AUC(0-τ),"Mean AUC(0-τ) for erlotinib and the OSI-420 metabolite were 29,997 ng∙h/mL and 3,020 ng∙h/mL, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"3,020",144661,DB00530,Erlotinib
,20094773,clearances,"Mean (SD) paclitaxel clearances (L/h/M(2)) were 11.7 (3.4) and 12.7 (6.7) in the placebo and erlotinib treatment groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[h·l] / [M(2],11.7,144662,DB00530,Erlotinib
,20094773,clearances,"Mean (SD) paclitaxel clearances (L/h/M(2)) were 11.7 (3.4) and 12.7 (6.7) in the placebo and erlotinib treatment groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[h·l] / [M(2],12.7,144663,DB00530,Erlotinib
,20094773,AUC(0-∞),"The resultant paclitaxel AUC(0-∞) (ng∙h/mL) was 18,400 (5,300) for the placebo group and 17,800 (5,500) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"18,400",144664,DB00530,Erlotinib
,20094773,AUC(0-∞),"The resultant paclitaxel AUC(0-∞) (ng∙h/mL) was 18,400 (5,300) for the placebo group and 17,800 (5,500) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"17,800",144665,DB00530,Erlotinib
,20094773,clearances,"For carboplatin, the mean (SD) clearances (L/h) were 16.8 (3.9) and 16.1 (4.4) for the placebo and erlotinib groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[l] / [h],16.8,144666,DB00530,Erlotinib
,20094773,clearances,"For carboplatin, the mean (SD) clearances (L/h) were 16.8 (3.9) and 16.1 (4.4) for the placebo and erlotinib groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[l] / [h],16.1,144667,DB00530,Erlotinib
,20094773,AUC(0-∞),"The resultant carboplatin AUC(0-∞) (ng/mL∙h) were 49,900 (9,700) for the placebo group and 48,400 (11,900) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng] / [ml∙h],"49,900",144668,DB00530,Erlotinib
,20094773,AUC(0-∞),"The resultant carboplatin AUC(0-∞) (ng/mL∙h) were 49,900 (9,700) for the placebo group and 48,400 (11,900) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng] / [ml∙h],"48,400",144669,DB00530,Erlotinib
,22237261,progression-free survival,The median progression-free survival was 39 days (range 21-432+ days).,A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237261/),d,39,145181,DB00530,Erlotinib
,29296076,particle sizes,"The average particle sizes and entrapment efficiency of PEGylation erlotinib liposomes are 102.4±3.1 nm and 85.3%±1.8%, respectively.",Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29296076/),nm,102.4,146681,DB00530,Erlotinib
,29296076,entrapment efficiency,"The average particle sizes and entrapment efficiency of PEGylation erlotinib liposomes are 102.4±3.1 nm and 85.3%±1.8%, respectively.",Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29296076/),%,85.3,146682,DB00530,Erlotinib
,24085777,Overall histologic response rate,"Overall histologic response rate was 63% (complete response, 43%; partial response, 14%; stable disease, 29%; and disease progression, 14%).",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),%,63,146992,DB00530,Erlotinib
,24085777,Overall histologic response rate,"Overall histologic response rate was 63% (complete response, 43%; partial response, 14%; stable disease, 29%; and disease progression, 14%).",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),%,43,146993,DB00530,Erlotinib
,24085777,Overall histologic response rate,"Overall histologic response rate was 63% (complete response, 43%; partial response, 14%; stable disease, 29%; and disease progression, 14%).",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),%,14,146994,DB00530,Erlotinib
,24085777,time to progression,"With median follow-up of 36 months, mean time to progression to higher-grade dysplasia or carcinoma was 25.4 months.",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),month,25.4,146995,DB00530,Erlotinib
,24085777,V/F,Larger average erlotinib V/F (approximately 308 L) and CL/F (8.3 L/h) compared with previous studies may be related to relatively large average bodyweights.,Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),l,308,146996,DB00530,Erlotinib
,24085777,CL/F,Larger average erlotinib V/F (approximately 308 L) and CL/F (8.3 L/h) compared with previous studies may be related to relatively large average bodyweights.,Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),[l] / [h],8.3,146997,DB00530,Erlotinib
,24085777,t1/2,Average erlotinib t1/2 was 25.6 hours.,Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),h,25.6,146998,DB00530,Erlotinib
,21938545,C (max),"The PK of erlotinib was similar between the two cohorts with a median C (max) of 1.09 versus 0.828 μg/mL and corresponding median AUC(0-t ) 29.3 versus 30.5 μg h/mL for the AHF and MHI cohorts, respectively.",An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21938545/),[μg] / [ml],1.09,149077,DB00530,Erlotinib
,21938545,C (max),"The PK of erlotinib was similar between the two cohorts with a median C (max) of 1.09 versus 0.828 μg/mL and corresponding median AUC(0-t ) 29.3 versus 30.5 μg h/mL for the AHF and MHI cohorts, respectively.",An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21938545/),[μg] / [ml],0.828,149078,DB00530,Erlotinib
,21938545,AUC(0-t ),"The PK of erlotinib was similar between the two cohorts with a median C (max) of 1.09 versus 0.828 μg/mL and corresponding median AUC(0-t ) 29.3 versus 30.5 μg h/mL for the AHF and MHI cohorts, respectively.",An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21938545/),[h·μg] / [ml],29.3,149079,DB00530,Erlotinib
,21938545,AUC(0-t ),"The PK of erlotinib was similar between the two cohorts with a median C (max) of 1.09 versus 0.828 μg/mL and corresponding median AUC(0-t ) 29.3 versus 30.5 μg h/mL for the AHF and MHI cohorts, respectively.",An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21938545/),[h·μg] / [ml],30.5,149080,DB00530,Erlotinib
,25891541,progression-free survival,The median progression-free survival (95% confidence interval) was 44.0 (22.0-133.0) days for the EGFR wild-type group (n=9) and 107.0 (74.0-224.0) days for the EGFR-activating mutation group (n=13).,Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25891541/),d,44.0,150388,DB00530,Erlotinib
,25891541,progression-free survival,The median progression-free survival (95% confidence interval) was 44.0 (22.0-133.0) days for the EGFR wild-type group (n=9) and 107.0 (74.0-224.0) days for the EGFR-activating mutation group (n=13).,Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25891541/),d,107.0,150389,DB00530,Erlotinib
,29175983,VT,"In patients, the VT of 11C-erlotinib did not increase after intake of elacridar (0.213 ± 0.12 vs. 0.205 ± 0.07, P = 0.91).",Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175983/),,0.213,151473,DB00530,Erlotinib
,29175983,VT,"In patients, the VT of 11C-erlotinib did not increase after intake of elacridar (0.213 ± 0.12 vs. 0.205 ± 0.07, P = 0.91).",Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175983/),,0.205,151474,DB00530,Erlotinib
,29175983,exposure,Elacridar exposure in patients was 401 ± 154 ng/mL.,Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175983/),[ng] / [ml],401,151475,DB00530,Erlotinib
,32631634,CL/F,"Average erlotinib CL/F with interindividual variability (%CV) was 3.8 L/h (41.5%), and V/F was 166 L (53.8%).",Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32631634/),[l] / [h],3.8,153436,DB00530,Erlotinib
,32631634,V/F,"Average erlotinib CL/F with interindividual variability (%CV) was 3.8 L/h (41.5%), and V/F was 166 L (53.8%).",Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32631634/),l,166,153437,DB00530,Erlotinib
,32631634,absorption rate constant,The absorption rate constant was 1.48 h-1.,Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32631634/),1/[h],1.48,153438,DB00530,Erlotinib
,23922054,CL,"The estimates for CL, central compartment volume (V1 ), and median terminal half-life were 0.439 L/day, 2.77 L, and 13.4 days, respectively.","Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23922054/),[l] / [d],0.439,156677,DB00530,Erlotinib
,23922054,central compartment volume (V1 ),"The estimates for CL, central compartment volume (V1 ), and median terminal half-life were 0.439 L/day, 2.77 L, and 13.4 days, respectively.","Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23922054/),l,2.77,156678,DB00530,Erlotinib
,23922054,terminal half-life,"The estimates for CL, central compartment volume (V1 ), and median terminal half-life were 0.439 L/day, 2.77 L, and 13.4 days, respectively.","Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23922054/),d,13.4,156679,DB00530,Erlotinib
,22609229,objective response rate,"The objective response rate was 20% (3/15 patients; 2 responders had mutant HER1, 1 responder had wild-type HER1), median overall progression-free survival was 9.3 weeks.","A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609229/),%,20,156981,DB00530,Erlotinib
,22609229,overall progression-free survival,"The objective response rate was 20% (3/15 patients; 2 responders had mutant HER1, 1 responder had wild-type HER1), median overall progression-free survival was 9.3 weeks.","A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609229/),weeks,9.3,156982,DB00530,Erlotinib
,22609229,maximum concentration,"Combination therapy did not affect erlotinib's pharmacokinetics; however, pertuzumab mean exposures (maximum concentration, 231 mg/L; area under the concentration-time curve from 0 to 21 days, 1780 mg*d/L) were slightly higher than in previous studies.","A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609229/),[mg] / [l],231,156983,DB00530,Erlotinib
,22609229,area under the concentration-time curve from 0 to 21 days,"Combination therapy did not affect erlotinib's pharmacokinetics; however, pertuzumab mean exposures (maximum concentration, 231 mg/L; area under the concentration-time curve from 0 to 21 days, 1780 mg*d/L) were slightly higher than in previous studies.","A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609229/),[d·mg] / [l],1780,156984,DB00530,Erlotinib
,18794549,apparent erlotinib clearance,The median apparent erlotinib clearance was 3.1 L/h/m(2) and the median terminal half-life was 8.7 hours.,Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794549/),[h·l] / [m(2],3.1,159978,DB00530,Erlotinib
,18794549,terminal half-life,The median apparent erlotinib clearance was 3.1 L/h/m(2) and the median terminal half-life was 8.7 hours.,Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794549/),h,8.7,159979,DB00530,Erlotinib
,21175992,overall survival,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),month,9.23,161000,DB00530,Erlotinib
,21175992,survival rate,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),%,33.0,161001,DB00530,Erlotinib
,21175992,survival rate,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),month,3.48,161002,DB00530,Erlotinib
,21175992,progression-free survival,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),month,3.48,161003,DB00530,Erlotinib
,21175992,overall response,"The overall response and disease control rates were 20.3% and 50.0%, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),%,20.3,161004,DB00530,Erlotinib
,21175992,disease control rates,"The overall response and disease control rates were 20.3% and 50.0%, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),%,50.0,161005,DB00530,Erlotinib
,28554216,relative bioavailability,The relative bioavailability of NUFS-Ert compared with that of Tarceva® was 550% and the ratio of the area under the concentration-time curve (AUC) of fed state to the AUC of fasted state was 1.8 for NUFS-Ert and 5.8 for Tarceva®.,Nanoparticulation improves bioavailability of Erlotinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28554216/),%,550,162789,DB00530,Erlotinib
,23532985,C0,"Interstitial lung disease (ILD)-like events occurred in 3 patients (3.4 %), and the median value of erlotinib C0 levels adjacent to these events was approximately 3 times higher than that in patients who did not develop ILD (3253 versus 1107 ng/mL; p = 0.014).",Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23532985/),[ng] / [ml],3253,162900,DB00530,Erlotinib
,23532985,C0,"Interstitial lung disease (ILD)-like events occurred in 3 patients (3.4 %), and the median value of erlotinib C0 levels adjacent to these events was approximately 3 times higher than that in patients who did not develop ILD (3253 versus 1107 ng/mL; p = 0.014).",Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23532985/),[ng] / [ml],1107,162901,DB00530,Erlotinib
,23532985,objective response rate,"The objective response rate in the EGFR wild-type group was marginally higher in patients achieving higher erlotinib C0 levels (≥1711 ng/mL) than that in patients having lower erlotinib C0 levels (38 versus 5 %; p = 0.058), whereas no greater response was observed in the higher group (67 %) versus the lower group (77 %) within EGFR mutation-positive patients (p = 0.62).",Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23532985/),,38,162902,DB00530,Erlotinib
,23532985,objective response rate,"The objective response rate in the EGFR wild-type group was marginally higher in patients achieving higher erlotinib C0 levels (≥1711 ng/mL) than that in patients having lower erlotinib C0 levels (38 versus 5 %; p = 0.058), whereas no greater response was observed in the higher group (67 %) versus the lower group (77 %) within EGFR mutation-positive patients (p = 0.62).",Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23532985/),,5,162903,DB00530,Erlotinib
,21681573,concentrations,"The plasma and CSF concentrations of erlotinib at a dose of 75 mg were 433 and 14 nM, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),,14,163535,DB00530,Erlotinib
,21681573,CSF,"The mean ± standard deviation of CSF concentrations and penetration rates were 106 ± 59 nM and 4.5 ± 1.5%, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),nM,106,163536,DB00530,Erlotinib
,21681573,concentrations,"The mean ± standard deviation of CSF concentrations and penetration rates were 106 ± 59 nM and 4.5 ± 1.5%, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),nM,106,163537,DB00530,Erlotinib
,21681573,penetration rates,"The mean ± standard deviation of CSF concentrations and penetration rates were 106 ± 59 nM and 4.5 ± 1.5%, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),%,4.5,163538,DB00530,Erlotinib
,17932674,terminal half-life,Erlotinib disappearance from plasma after a short IV infusion was biexponential with a mean terminal half-life of 5.2 h and a mean clearance of 128 ml/min per m(2).,The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17932674/),h,5.2,163583,DB00530,Erlotinib
,17932674,clearance,Erlotinib disappearance from plasma after a short IV infusion was biexponential with a mean terminal half-life of 5.2 h and a mean clearance of 128 ml/min per m(2).,The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17932674/),[min·ml] / [m(2],128,163584,DB00530,Erlotinib
,23490650,MTD,"In phase I (n=28), the MTD was determined to be 200mg daily.","Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23490650/),mg,200,164388,DB00530,Erlotinib
,23490650,objective response rates,"Disease control (≥4months) and objective response rates, respectively, were 43.3% and 3.3% (cohort A) and 22.6% and 3.2% (cohort B).","Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23490650/),%,3.3,164389,DB00530,Erlotinib
,23490650,objective response rates,"Disease control (≥4months) and objective response rates, respectively, were 43.3% and 3.3% (cohort A) and 22.6% and 3.2% (cohort B).","Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23490650/),%,22.6,164390,DB00530,Erlotinib
,23490650,objective response rates,"Disease control (≥4months) and objective response rates, respectively, were 43.3% and 3.3% (cohort A) and 22.6% and 3.2% (cohort B).","Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23490650/),%,3.2,164391,DB00530,Erlotinib
,30087553,drug loading amount,"The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively.",HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087553/),%,5.6,167418,DB00530,Erlotinib
,30087553,encap,"The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively.",HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087553/),%,5.6,167419,DB00530,Erlotinib
,30087553,encap,"The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively.",HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087553/),%,81.2,167420,DB00530,Erlotinib
,28444958,clearance,"Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test).",Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444958/),[l] / [h],3.15,168505,DB00530,Erlotinib
,28444958,clearance,"Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test).",Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444958/),[l] / [h],3.93,168506,DB00530,Erlotinib
,25260842,Cmax,"Patients received escalating doses of tasisulam (3 + 3 schema; target Cmax 300-400 μg/mL) every 28 days plus 1,000 mg/m(2) gemcitabine HCl (days 1 and 15), 60 mg/m(2) docetaxel, 200 mg/m(2)/day temozolomide, 75 mg/m(2) cisplatin, or 150 mg/day erlotinib.","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[μg] / [ml],300-400,170080,DB00530,Erlotinib
,25260842,AUCalb),"Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[h·μg] / [ml],"3,500",170081,DB00530,Erlotinib
,25260842,AUCalb),"Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[h·μg] / [ml],"4,000",170082,DB00530,Erlotinib
,32759036,oral bioavailability,The oral bioavailability was 50.29 %.,"Development and validation of a highly sensitive HPLC-MS/MS method for the QAP14, a novel potential anti-cancer agent, in rat plasma and its application to a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32759036/),%,50.29,173158,DB00530,Erlotinib
,22160298,clearance,The mean clearance was 5.75 L/h for erlotinib and 53.8 L/h for enzastaurin.,A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22160298/),[l] / [h],5.75,174691,DB00530,Erlotinib
,22160298,clearance,The mean clearance was 5.75 L/h for erlotinib and 53.8 L/h for enzastaurin.,A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22160298/),[l] / [h],53.8,174692,DB00530,Erlotinib
,25296722,m/z,"The m/z values of the precursor and product ions for the analytes were as follows: erlotinib, 394.2/278.2; and OSI-413 and OSI-420, 380.2/278.2.",Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25296722/),,380,179179,DB00530,Erlotinib
,25296722,total run time,The total run time was 21 min and no peaks interfering with the analytes and internal standard (d6 -erlotinib) in human plasma were observed.,Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25296722/),min,21,179180,DB00530,Erlotinib
>,25296722,recovery ratios,The pretreatment recovery ratios were >86.1%.,Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25296722/),%,86.1,179181,DB00530,Erlotinib
,24857345,overall survival rate,"Median survival was 3.8 months, and 6 month overall survival rate was 32% (95% CI 19-47%).",A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24857345/),%,32,180087,DB00530,Erlotinib
,21753156,MTD,The MTD was 40 mg LY2334737.,Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753156/),mg,40,185075,DB00530,Erlotinib
,21753156,accumulation index,"The metabolite 2',2'-difluorodeoxyuridine accumulated with an accumulation index of 4.3 (coefficient of variation: 20%).",Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753156/),,4.3,185076,DB00530,Erlotinib
,21753156,MTD,LY2334737 displays linear pharmacokinetics and the MTD is 40 mg with or without daily administration of 100 mg erlotinib.,Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753156/),mg,40,185077,DB00530,Erlotinib
,24388705,serum T1 drug levels,"Patients with grade 3 skin toxicity showed serum T1 drug levels significantly higher than those with grade 0-2 (6.84 [2.28] vs. 3.08 [1.97] μmol/l, respectively, p=0.004) and had longer progression-free and overall survival.","Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388705/),[μM] / [l],6.84,187425,DB00530,Erlotinib
,24388705,serum T1 drug levels,"Patients with grade 3 skin toxicity showed serum T1 drug levels significantly higher than those with grade 0-2 (6.84 [2.28] vs. 3.08 [1.97] μmol/l, respectively, p=0.004) and had longer progression-free and overall survival.","Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388705/),[μM] / [l],3.08,187426,DB00530,Erlotinib
,27036206,Maximal tolerated dose (MTD),Maximal tolerated dose (MTD) was determined to be 1 mg/kg/day.,A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036206/),[mg] / [d·kg],1,187610,DB00530,Erlotinib
,27287856,disease control rate,"In the etoposide arm, 2 patients (16.7 %) demonstrated partial responses, 1 (8.3 %) patient demonstrated a minor response, and 2 (16.7 %) showed prolonged stable disease, for a prolonged disease control rate of 41.7 %.",Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27287856/),,41,191902,DB00530,Erlotinib
,25594896,total run time,The total run time was 7 min.,"A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594896/),min,7,193370,DB00530,Erlotinib
above,25594896,Extraction recovery,"Extraction recovery was above 89%, 99% and 89% for erlotinib, OSI-420 and didesmethyl erlotinib, respectively.","A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594896/),%,89,193371,DB00530,Erlotinib
,25594896,Extraction recovery,"Extraction recovery was above 89%, 99% and 89% for erlotinib, OSI-420 and didesmethyl erlotinib, respectively.","A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594896/),%,99,193372,DB00530,Erlotinib
,25594896,Extraction recovery,"Extraction recovery was above 89%, 99% and 89% for erlotinib, OSI-420 and didesmethyl erlotinib, respectively.","A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594896/),%,89,193373,DB00530,Erlotinib
,24448640,maximum tolerated dosage,The maximum tolerated dosage was determined to be 1.0 mg/m(2).,Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24448640/),[mg] / [m(2],1.0,193815,DB00530,Erlotinib
,34036220,overall response rate (ORR),"The overall response rate (ORR) and DCR in dose-expansion cohort A was 50% and 50%, respectively.",Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34036220/),%,50,194602,DB00530,Erlotinib
,34036220,overall response rate (ORR),"The overall response rate (ORR) and DCR in dose-expansion cohort A was 50% and 50%, respectively.",Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34036220/),,50,194603,DB00530,Erlotinib
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,85,195812,DB00530,Erlotinib
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,71.5,195813,DB00530,Erlotinib
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,37.85-41.19,195814,DB00530,Erlotinib
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,31.8,195815,DB00530,Erlotinib
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,39.53,195816,DB00530,Erlotinib
,33735711,IC50,The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).,"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,0.27-0.78,195817,DB00530,Erlotinib
,33735711,IC50,The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).,"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,0.18,195818,DB00530,Erlotinib
,33735711,IC50,The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).,"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,0.21,195819,DB00530,Erlotinib
,20479691,CSF,"The mean +/- SD CSF concentrations of erlotinib and OSI-420 were 54 +/- 30 ng/ml and 10.8 +/- 8.2 ng/ml, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),[ng] / [ml],54,199883,DB00530,Erlotinib
,20479691,CSF,"The mean +/- SD CSF concentrations of erlotinib and OSI-420 were 54 +/- 30 ng/ml and 10.8 +/- 8.2 ng/ml, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),[ng] / [ml],10.8,199884,DB00530,Erlotinib
,20479691,concentrations,"The mean +/- SD CSF concentrations of erlotinib and OSI-420 were 54 +/- 30 ng/ml and 10.8 +/- 8.2 ng/ml, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),[ng] / [ml],54,199885,DB00530,Erlotinib
,20479691,concentrations,"The mean +/- SD CSF concentrations of erlotinib and OSI-420 were 54 +/- 30 ng/ml and 10.8 +/- 8.2 ng/ml, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),[ng] / [ml],10.8,199886,DB00530,Erlotinib
,20479691,CSF,"The mean +/- SD CSF penetration rates of erlotinib and OSI-420 were 5.1% +/- 1.9% and 5.8% +/- 3.6%, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),%,5.1,199887,DB00530,Erlotinib
,20479691,penetration rates,"The mean +/- SD CSF penetration rates of erlotinib and OSI-420 were 5.1% +/- 1.9% and 5.8% +/- 3.6%, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),%,5.1,199888,DB00530,Erlotinib
,20479691,penetration rates,"The mean +/- SD CSF penetration rates of erlotinib and OSI-420 were 5.1% +/- 1.9% and 5.8% +/- 3.6%, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),%,5.8,199889,DB00530,Erlotinib
,20479691,CSF penetrations,"The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),%,5.1,199890,DB00530,Erlotinib
,20479691,CSF penetrations,"The CSF penetrations of erlotinib and OSI-420 in patients with NSCLC who had CNS metastases were approximately 5.1% and 5.8%, respectively.",Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20479691/),%,5.8,199891,DB00530,Erlotinib
,18723475,bioavailability,"In vivo, systemic exposure (P = 0.01) as well as bioavailability of erlotinib after oral administration (5 mg/kg) were statistically significantly increased in Bcrp1/Mdr1a/1b(-/-) knockout mice (60.4%) compared with WT mice (40.0%; P = 0.02).","Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723475/),%,60.4,201768,DB00530,Erlotinib
,18723475,bioavailability,"In vivo, systemic exposure (P = 0.01) as well as bioavailability of erlotinib after oral administration (5 mg/kg) were statistically significantly increased in Bcrp1/Mdr1a/1b(-/-) knockout mice (60.4%) compared with WT mice (40.0%; P = 0.02).","Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18723475/),%,40.0,201769,DB00530,Erlotinib
,32407455,disease control rate,"The disease control rate was 90.0% (90% CI, 82.7%-94.9%), median progression-free survival was 9.3 months (95% CI, 7.2-11.4 months), and median overall survival was 26.2 months (95% CI, 21.9-30.4 months).",Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32407455/),%,90.,204192,DB00530,Erlotinib
,32407455,progression-free survival,"The disease control rate was 90.0% (90% CI, 82.7%-94.9%), median progression-free survival was 9.3 months (95% CI, 7.2-11.4 months), and median overall survival was 26.2 months (95% CI, 21.9-30.4 months).",Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32407455/),month,9.3,204193,DB00530,Erlotinib
,32407455,overall survival,"The disease control rate was 90.0% (90% CI, 82.7%-94.9%), median progression-free survival was 9.3 months (95% CI, 7.2-11.4 months), and median overall survival was 26.2 months (95% CI, 21.9-30.4 months).",Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32407455/),month,26.2,204194,DB00530,Erlotinib
,32407455,plasma concentration,The median (range) erlotinib plasma concentration was measured at 685 (153-1950) ng/mL.,Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32407455/),[ng] / [ml],685,204195,DB00530,Erlotinib
,21208844,progression-free survival,"The Response Evaluation Criteria in Solid Tumors response rate was 11 of 14 (78%), median progression-free survival was 9.5 months, and median overall survival was 30 months.","Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),month,9.5,204548,DB00530,Erlotinib
,21208844,overall survival,"The Response Evaluation Criteria in Solid Tumors response rate was 11 of 14 (78%), median progression-free survival was 9.5 months, and median overall survival was 30 months.","Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),month,30,204549,DB00530,Erlotinib
,21208844,MTD,The MTD of erlotinib with FOLFOX4 with or without bevacizumab is 100 mg daily.,"Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21208844/),mg,100,204550,DB00530,Erlotinib
,24903027,bioavailability,The bioavailability of FA was sufficient (58 %) to suggest that FA may be viable as an orally administered medication.,Determination of oral bioavailability of fusaric acid in male Sprague-Dawley rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24903027/),%,58,205636,DB00530,Erlotinib
,21775215,percentage of penetration,"The mean percentage of penetration from plasma to pleural effusion for erlotinib was 18% on day 1 and 112% on day 8, while these values for OSI-420 were 9.5% on day 1 and 131% on day 8.",Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21775215/),%,18,208760,DB00530,Erlotinib
,21775215,percentage of penetration,"The mean percentage of penetration from plasma to pleural effusion for erlotinib was 18% on day 1 and 112% on day 8, while these values for OSI-420 were 9.5% on day 1 and 131% on day 8.",Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21775215/),%,112,208761,DB00530,Erlotinib
,21775215,percentage of penetration,"The mean percentage of penetration from plasma to pleural effusion for erlotinib was 18% on day 1 and 112% on day 8, while these values for OSI-420 were 9.5% on day 1 and 131% on day 8.",Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21775215/),%,9.5,208762,DB00530,Erlotinib
,21775215,percentage of penetration,"The mean percentage of penetration from plasma to pleural effusion for erlotinib was 18% on day 1 and 112% on day 8, while these values for OSI-420 were 9.5% on day 1 and 131% on day 8.",Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21775215/),%,131,208763,DB00530,Erlotinib
,21775215,area under the drug concentration-time curve,"The area under the drug concentration-time curve of pleural fluid for erlotinib was 28,406 ng-hr/mL for case 2 and 45,906 ng-hr/mL for case 4.",Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21775215/),[ng-hr] / [ml],"28,406",208764,DB00530,Erlotinib
,21775215,area under the drug concentration-time curve,"The area under the drug concentration-time curve of pleural fluid for erlotinib was 28,406 ng-hr/mL for case 2 and 45,906 ng-hr/mL for case 4.",Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21775215/),[ng-hr] / [ml],"45,906",208765,DB00530,Erlotinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.41,212573,DB00530,Erlotinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.39,212574,DB00530,Erlotinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.57,212575,DB00530,Erlotinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.24,212576,DB00530,Erlotinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.21,212577,DB00530,Erlotinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.31,212578,DB00530,Erlotinib
,17575239,Cl(max),"CYP2D6 was involved in gefitinib metabolism (Cl(max), 0.63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0.15 mL/min/nmol).",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.63,212579,DB00530,Erlotinib
,17575239,Cl(max),"CYP2D6 was involved in gefitinib metabolism (Cl(max), 0.63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0.15 mL/min/nmol).",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.15,212580,DB00530,Erlotinib
,17634483,Apparent oral clearance,"Apparent oral clearance (mean +/- standard deviation) was cohort dependent as follows: 1.9 +/- 0.2 L/h in cohort 1; 3.7 +/- 4.7 L/h in cohort 1a; 2.4 +/- 1.1 L/h in cohort 2; and 4.5 +/- 2.7 L/h in cohort 3 (Kruskal-Wallis, P < .017).",Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634483/),[l] / [h],1.9,213862,DB00530,Erlotinib
,17634483,Apparent oral clearance,"Apparent oral clearance (mean +/- standard deviation) was cohort dependent as follows: 1.9 +/- 0.2 L/h in cohort 1; 3.7 +/- 4.7 L/h in cohort 1a; 2.4 +/- 1.1 L/h in cohort 2; and 4.5 +/- 2.7 L/h in cohort 3 (Kruskal-Wallis, P < .017).",Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634483/),[l] / [h],3.7,213863,DB00530,Erlotinib
,17634483,Apparent oral clearance,"Apparent oral clearance (mean +/- standard deviation) was cohort dependent as follows: 1.9 +/- 0.2 L/h in cohort 1; 3.7 +/- 4.7 L/h in cohort 1a; 2.4 +/- 1.1 L/h in cohort 2; and 4.5 +/- 2.7 L/h in cohort 3 (Kruskal-Wallis, P < .017).",Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634483/),[l] / [h],2.4,213864,DB00530,Erlotinib
,17634483,Apparent oral clearance,"Apparent oral clearance (mean +/- standard deviation) was cohort dependent as follows: 1.9 +/- 0.2 L/h in cohort 1; 3.7 +/- 4.7 L/h in cohort 1a; 2.4 +/- 1.1 L/h in cohort 2; and 4.5 +/- 2.7 L/h in cohort 3 (Kruskal-Wallis, P < .017).",Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634483/),[l] / [h],4.5,213865,DB00530,Erlotinib
,19147777,MTD,MTD of erlotinib was 120 mg/m(2) per day.,"Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19147777/),[mg] / [d·m(2)],120,216547,DB00530,Erlotinib
,19147777,MTD,"Although the MTD of erlotinib in children with newly diagnosed high-grade glioma was 120 mg/m(2) per day, pharmacokinetic studies showed wide interpatient variability in drug exposure.","Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19147777/),[mg] / [m],120,216548,DB00530,Erlotinib
,20974795,RD,The RD of erlotinib was 125 mg/m² per day as monotherapy or in combination with radiotherapy.,Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974795/),[mg] / [d·m²],125,217596,DB00530,Erlotinib
,20974795,overall survival,"In group 2, overall survival was 12.0 months.",Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974795/),month,12.0,217597,DB00530,Erlotinib
,20974795,apparent clearance,"Mean (95% CI) apparent clearance and volume of distribution for erlotinib were 4.0 L/h (3.4-4.5 L/h) and 98.6 L (69.8-127.0 L), respectively, and were independent of the dose level; mean half-life was 16.6 hours.",Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974795/),[l] / [h],4.0,217598,DB00530,Erlotinib
,20974795,volume of distribution,"Mean (95% CI) apparent clearance and volume of distribution for erlotinib were 4.0 L/h (3.4-4.5 L/h) and 98.6 L (69.8-127.0 L), respectively, and were independent of the dose level; mean half-life was 16.6 hours.",Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974795/),l,98.6,217599,DB00530,Erlotinib
,20974795,half-life,"Mean (95% CI) apparent clearance and volume of distribution for erlotinib were 4.0 L/h (3.4-4.5 L/h) and 98.6 L (69.8-127.0 L), respectively, and were independent of the dose level; mean half-life was 16.6 hours.",Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974795/),h,16.6,217600,DB00530,Erlotinib
,24440798,m/z,The monitored transitions were m/z 501.2→182.1 for simotinib and m/z 394.4→278.1 for erlotinib.,"LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),,501.2,218103,DB00530,Erlotinib
,24440798,m/z,The monitored transitions were m/z 501.2→182.1 for simotinib and m/z 394.4→278.1 for erlotinib.,"LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),,182.1,218104,DB00530,Erlotinib
,24440798,m/z,The monitored transitions were m/z 501.2→182.1 for simotinib and m/z 394.4→278.1 for erlotinib.,"LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),,394.4,218105,DB00530,Erlotinib
,24440798,m/z,The monitored transitions were m/z 501.2→182.1 for simotinib and m/z 394.4→278.1 for erlotinib.,"LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),,278.1,218106,DB00530,Erlotinib
,24440798,Cmax,"The mean Cmax and Tmax for simotinib were 254.79±98.30 μg L(-1) and 1.71±0.48 h, respectively.","LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),[μg] / [l],254.79,218107,DB00530,Erlotinib
,24440798,Tmax,"The mean Cmax and Tmax for simotinib were 254.79±98.30 μg L(-1) and 1.71±0.48 h, respectively.","LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),h,1.71,218108,DB00530,Erlotinib
,24440798,t1/2,Plasma concentrations declined with a t1/2 of 5.37±2.32 h.,"LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),h,5.37,218109,DB00530,Erlotinib
,24440798,AUC0-t,"AUC0-t and AUC0→∞ values obtained were 1262.59±501.41 μg L(-1) h and 1329.95±517.42 μg L(-1) h, respectively.","LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),[h·μg] / [l],1262.59,218110,DB00530,Erlotinib
,24440798,AUC0→∞,"AUC0-t and AUC0→∞ values obtained were 1262.59±501.41 μg L(-1) h and 1329.95±517.42 μg L(-1) h, respectively.","LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: application to a pharmacokinetic study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440798/),[h·μg] / [l],1329.95,218111,DB00530,Erlotinib
,21088257,P(Brain),"P(Brain) in wild-type mice was 0.27 ± 0.11 and 0.07 ± 0.02 (mean ± SD) for erlotinib and OSI-420, respectively.",Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088257/),,0.27,219850,DB00530,Erlotinib
,21088257,P(Brain),"P(Brain) in wild-type mice was 0.27 ± 0.11 and 0.07 ± 0.02 (mean ± SD) for erlotinib and OSI-420, respectively.",Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088257/),,0.07,219851,DB00530,Erlotinib
,29453635,Trough plasma concentrations,Trough plasma concentrations ranged from 0.04 to 1.22 µg/ml after day 1 and from 0.01 to 2.4 µg/ml in the long-term assessment.,Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453635/),[μg] / [ml],0.04 to 1.22,224474,DB00530,Erlotinib
,29453635,Trough plasma concentrations,Trough plasma concentrations ranged from 0.04 to 1.22 µg/ml after day 1 and from 0.01 to 2.4 µg/ml in the long-term assessment.,Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453635/),[μg] / [ml],0.01 to 2.4,224475,DB00530,Erlotinib
,24429877,Disease control rates,Disease control rates were 54% for NSCLC (n = 26) and 43% for head and neck cancer (n = 7).,"A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24429877/),%,54,224800,DB00530,Erlotinib
,24429877,Disease control rates,Disease control rates were 54% for NSCLC (n = 26) and 43% for head and neck cancer (n = 7).,"A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24429877/),%,43,224801,DB00530,Erlotinib
,24429877,progression-free survival (PFS),"For EGFR-mutant versus EGFR wild-type patients, progression-free survival (PFS) was 4.7 versus 1.9 months (P = 0.43) and overall survival was 41 (estimated) versus 5.2 months (P = 0.39).","A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24429877/),month,4.7,224802,DB00530,Erlotinib
,24429877,progression-free survival (PFS),"For EGFR-mutant versus EGFR wild-type patients, progression-free survival (PFS) was 4.7 versus 1.9 months (P = 0.43) and overall survival was 41 (estimated) versus 5.2 months (P = 0.39).","A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24429877/),month,1.9,224803,DB00530,Erlotinib
,24429877,overall survival,"For EGFR-mutant versus EGFR wild-type patients, progression-free survival (PFS) was 4.7 versus 1.9 months (P = 0.43) and overall survival was 41 (estimated) versus 5.2 months (P = 0.39).","A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24429877/),month,41,224804,DB00530,Erlotinib
,24429877,overall survival,"For EGFR-mutant versus EGFR wild-type patients, progression-free survival (PFS) was 4.7 versus 1.9 months (P = 0.43) and overall survival was 41 (estimated) versus 5.2 months (P = 0.39).","A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24429877/),month,5.2,224805,DB00530,Erlotinib
,15753462,overall survival,"The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months.",Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15753462/),month,12.6,227006,DB00530,Erlotinib
,15753462,progression-free survival,"The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months.",Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15753462/),month,6.2,227007,DB00530,Erlotinib
,17189413,AUC,"Patients with advanced solid malignancies were treated continuously with erlotinib at doses of 100, 125, and 150 mg/d orally along with fixed i.v. doses of paclitaxel 225 mg/m(2) and carboplatin AUC 6 mg x min/mL, both on day 1 every 3 weeks.","Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17189413/),[mg·min] / [ml],6,227158,DB00530,Erlotinib
,21791058,MTD,The MTD of motesanib in combination with gemcitabine and erlotinib was 100 mg QD.,Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21791058/),mg,100,229474,DB00530,Erlotinib
,22878749,overall response rate,"One patient had a partial response to erlotinib/HCQ, for an overall response rate of 5% (95% confidence interval, 1-25).",A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22878749/),%,5,230952,DB00530,Erlotinib
,23334925,absolute bioavailability,"Friend Leukemia Virus Strain B (FVB) mice were used to determine the bioavailability of elacridar after a 10 mg/kg dose of elacridar in the microemulsion, intraperitoneally (i.p.) and orally (p.o.); and the absolute bioavailability was determined to be 1.3 and 0.47, respectively.",Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334925/),,1.3,233430,DB00530,Erlotinib
,23334925,absolute bioavailability,"Friend Leukemia Virus Strain B (FVB) mice were used to determine the bioavailability of elacridar after a 10 mg/kg dose of elacridar in the microemulsion, intraperitoneally (i.p.) and orally (p.o.); and the absolute bioavailability was determined to be 1.3 and 0.47, respectively.",Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334925/),,0.47,233431,DB00530,Erlotinib
,16490804,absolute oral bioavailability,"The mean absolute oral bioavailability, using compartmental analysis, was estimated as 59% (95% confidence interval, 55%-63%).","Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490804/),%,59,242490,DB00530,Erlotinib
,16490804,bioavailability,Both intravenous and oral erlotinib were generally well tolerated with an estimated bioavailability of 59% following oral administration.,"Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490804/),%,59,242491,DB00530,Erlotinib
,20395213,nonprogression rate,The nonprogression rate at 6 weeks was 74%: 12 (24%) partial response and 25 (50%) stable disease.,A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),%,74,244829,DB00530,Erlotinib
,20395213,time to progression,"Median time to progression was 5.0 months [95% confidence interval (95% CI), 3.2-6.8 months].",A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),month,5.0,244830,DB00530,Erlotinib
,20395213,overall survival,"Median overall survival was 10.9 months (95% CI, 3.8-18.1 months).",A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),month,10.9,244831,DB00530,Erlotinib
,21220471,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 45 mg/d.,"Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220471/),[mg] / [d],45,247433,DB00530,Erlotinib
,21220471,MTD,The MTD of PF299804 is 45 mg/d.,"Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220471/),[mg] / [d],45,247434,DB00530,Erlotinib
,16857821,overall survival,"The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months.",Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16857821/),month,12.6,247915,DB00530,Erlotinib
,16857821,progression-free survival,"The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months.",Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16857821/),month,6.2,247916,DB00530,Erlotinib
,20490801,CL/F,"The CL/F (~7 L/h), V/F (~140 L), and t1/2 (~20 h) for erlotinib were similar to the reported.",Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490801/),[l] / [h],7,249207,DB00530,Erlotinib
,20490801,V/F,"The CL/F (~7 L/h), V/F (~140 L), and t1/2 (~20 h) for erlotinib were similar to the reported.",Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490801/),l,140,249208,DB00530,Erlotinib
,20490801,t1/2,"The CL/F (~7 L/h), V/F (~140 L), and t1/2 (~20 h) for erlotinib were similar to the reported.",Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490801/),h,20,249209,DB00530,Erlotinib
,25521398,overall survival,"Median PFS was 15.4 weeks (95% CI, 9.7-17.6); median overall survival was 46.3 weeks (95% CI, 32.7-not reached); and the objective response rate was 17.1% (95% CI, 7.2-32.1).",Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25521398/),weeks,46.3,249892,DB00530,Erlotinib
,25521398,objective response rate,"Median PFS was 15.4 weeks (95% CI, 9.7-17.6); median overall survival was 46.3 weeks (95% CI, 32.7-not reached); and the objective response rate was 17.1% (95% CI, 7.2-32.1).",Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25521398/),%,17.1,249893,DB00530,Erlotinib
,19164205,steady-state trough erlotinib plasma concentrations,"Median steady-state trough erlotinib plasma concentrations were 0.375 and 1.22 microg/mL for 150 mg and 300 mg, respectively.",Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164205/),[μg] / [ml],0.375,253543,DB00530,Erlotinib
,19164205,steady-state trough erlotinib plasma concentrations,"Median steady-state trough erlotinib plasma concentrations were 0.375 and 1.22 microg/mL for 150 mg and 300 mg, respectively.",Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164205/),[μg] / [ml],1.22,253544,DB00530,Erlotinib
,19164205,MTD,The MTD of erlotinib in NSCLC patients who smoke was 300 mg.,Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164205/),mg,300,253545,DB00530,Erlotinib
,26831715,MTDs,"MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2).",Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26831715/),mg,450,257700,DB00530,Erlotinib
,26831715,MTDs,"MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2).",Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26831715/),,400,257701,DB00530,Erlotinib
,26214085,overall response rate,"The overall response rate was 33%, including 3 partial responses, in the 9 patients.","Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26214085/),%,33,259066,DB00530,Erlotinib
,26214085,progression-free survival,"The median progression-free survival for all patients was quite long, 11.3 months, and the median overall survival has not yet been reached.","Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26214085/),month,11.3,259067,DB00530,Erlotinib
,17149608,progression-free survival,"Patients with unresectable or metastatic pancreatic cancer (n = 15) had a median progression-free survival of 289 days, the estimated overall survival of 389 days (12.5 months), and a 1-year survival rate of 51%.",Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149608/),d,289,259700,DB00530,Erlotinib
,17149608,overall survival,"Patients with unresectable or metastatic pancreatic cancer (n = 15) had a median progression-free survival of 289 days, the estimated overall survival of 389 days (12.5 months), and a 1-year survival rate of 51%.",Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149608/),d,389,259701,DB00530,Erlotinib
,23328813,overall survival,The median overall survival was 5.7 months.,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328813/),month,5.7,261872,DB00530,Erlotinib
,23328813,Progression-free survival,Progression-free survival at 6 months was 14%.,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328813/),%,14,261873,DB00530,Erlotinib
,25917840,flow rate,The chromatographic separation was achieved on a C18 column with gradient elution by using a mixture of 0.1% formic acid aqueous solution and acetonitrile as the mobile phase at a flow rate of 0.3mL/min.,Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25917840/),[ml] / [min],0.3,268287,DB00530,Erlotinib
,25917840,half-life (t1/2),"The mean half-life (t1/2) was between 1 and 5h, and the metabolites were eliminated faster than the parent constituents.",Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25917840/),h,1 and 5,268288,DB00530,Erlotinib
,25917840,time to reach maximum plasma concentration (Tmax),The median (range) time to reach maximum plasma concentration (Tmax) was between 0.5 and 1h.,Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25917840/),h,0.5 and 1,268289,DB00530,Erlotinib
,29995672,plasma concentrations,"Patients with grade ≥2 rash had higher plasma concentrations of erlotinib compared with those with grade ≤1 [1.02 (0.43-2.60) versus 0.67 (0.10-1.85) mcg/mL, P < 0.01].",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),[mcg] / [ml],1.02,271242,DB00530,Erlotinib
,29995672,plasma concentrations,"Patients with grade ≥2 rash had higher plasma concentrations of erlotinib compared with those with grade ≤1 [1.02 (0.43-2.60) versus 0.67 (0.10-1.85) mcg/mL, P < 0.01].",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),[mcg] / [ml],0.67,271243,DB00530,Erlotinib
,29995672,C/D ratios,"The C/D ratios of erlotinib in the PPI and H2RB groups were lower than that in the control group [0.39 (0.08-0.76) and 0.48 (0.33-0.81) versus 0.51 (0.28-1.28) mcg·mL·mg·kg], where statistical significance was observed between PPI and control groups (P < 0.05).",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),kg·mcg·mg·ml,0.39,271244,DB00530,Erlotinib
,29995672,C/D ratios,"The C/D ratios of erlotinib in the PPI and H2RB groups were lower than that in the control group [0.39 (0.08-0.76) and 0.48 (0.33-0.81) versus 0.51 (0.28-1.28) mcg·mL·mg·kg], where statistical significance was observed between PPI and control groups (P < 0.05).",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),kg·mcg·mg·ml,0.48,271245,DB00530,Erlotinib
,29995672,C/D ratios,"The C/D ratios of erlotinib in the PPI and H2RB groups were lower than that in the control group [0.39 (0.08-0.76) and 0.48 (0.33-0.81) versus 0.51 (0.28-1.28) mcg·mL·mg·kg], where statistical significance was observed between PPI and control groups (P < 0.05).",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),kg·mcg·mg·ml,0.51,271246,DB00530,Erlotinib
,29995672,oral CL/F,"The population pharmacokinetic estimated oral CL/F in the PPI and H2RB groups were higher than that in the control group [5.55 (3.36-14.52) and 4.82 (2.08-6.32) versus 3.95 (2.01-10.44) L/h], where statistical significance was observed between PPI and control groups (P < 0.05).",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),[l] / [h],5.55,271247,DB00530,Erlotinib
,29995672,oral CL/F,"The population pharmacokinetic estimated oral CL/F in the PPI and H2RB groups were higher than that in the control group [5.55 (3.36-14.52) and 4.82 (2.08-6.32) versus 3.95 (2.01-10.44) L/h], where statistical significance was observed between PPI and control groups (P < 0.05).",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),[l] / [h],4.82,271248,DB00530,Erlotinib
,29995672,oral CL/F,"The population pharmacokinetic estimated oral CL/F in the PPI and H2RB groups were higher than that in the control group [5.55 (3.36-14.52) and 4.82 (2.08-6.32) versus 3.95 (2.01-10.44) L/h], where statistical significance was observed between PPI and control groups (P < 0.05).",Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29995672/),[l] / [h],3.95,271249,DB00530,Erlotinib
,26966895,flow rate,"Chromatographic separation was performed on a Waters BEH C18 column with an isocratic elution using a mobile phase composed of acetonitrile and water, each with 0.1% formic acid, (80: 20, v/v), at a flow rate of 0.2 mL/min.",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),[ml] / [min],0.2,273626,DB00530,Erlotinib
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,36,273627,DB00530,Erlotinib
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,147.02,273628,DB00530,Erlotinib
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,170.16,273629,DB00530,Erlotinib
,26966895,Er%,The method provided good extraction recovery of all analytes from rat plasma (Er% from -14.05 to -1.08).,Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,1,273630,DB00530,Erlotinib
